American Society of Hematology

SHERPA: Blue

People

  1. Palomba
    Palomba
  2. Zelenetz
    Zelenetz
  3. Seshan
    Seshan
  4. Noy
    Noy
  5. Younes
    Younes
  6. Batlevi
    Batlevi
  7. Matasar
    Matasar
  8. Hamilton
    Hamilton
  9. Hamlin
    Hamlin
  10. Horwitz
    Horwitz

Groups

  1. Biostatistics Service (15)
  2. Center for Hematologic Malignancies (15)
  3. Center for Pancreatic Cancer Research (15)
  4. Department of Medicine (15)
  5. Epidemiology and Biostatistics (15)
  6. Hematologic Malignancies, Division of (15)
  7. Lymphoma (15)
  8. Executive Committee, Center for Hematologic Malignancies (14)
  9. Survivorship Research (12)
  10. GSK Faculty (10)
Search Within
  1. "Center for Pancreatic Cancer Research"
  2. "Lymphoma"
  3. "Maria Palomba"
Formats
  1. Meeting Abstract (13)
  2. Journal Article (2)
Groups
  1. Biostatistics Service (15)
  2. Center for Hematologic Malignancies (15)
  3. Center for Pancreatic Cancer Research (15)
  4. Department of Medicine (15)
  5. Epidemiology and Biostatistics (15)
  6. Hematologic Malignancies, Division of (15)

More Groups

People
  1. Andrew Zelenetz (15)
  2. Maria Palomba (15)
  3. Venkatraman Seshan (14)
  4. Anas Younes (12)
  5. Ariela Noy (12)
  6. Ahmet Dogan (11)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2021 (3)
  4. 2020 (2)
  5. 2019 (1)
  6. 2017 (1)

More Years

Publications
  1. Blood (14)
  2. Blood Advances (1)

Results (15)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
    Journal Article

    Bobillo, S.; Joffe, E.; Lavery, J. A.; Sermer, D.; Ghione, P.; Noy, A.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim analysis from a prospective multicenter study of next-generation sequencing minimal residual disease assessment and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma
    Meeting Abstract

    Kumar, A.; Westin, J.; Schuster, S. J.; Nowakowski, G. S.; Lossos, I. S.; Batlevi, C. L.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma
    Journal Article

    Sermer, D.; Bobillo, S.; Dogan, A.; Zhang, Y.; Seshan, V.; Lavery, J. A.; Batlevi, C.; Caron, P.; Hamilton, A.; Hamlin, P.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Central nervous system prophylaxis with high-dose intravenous methotrexate or intrathecal chemotherapy in patients with diffuse large B-cell lymphoma and high-risk of CNS relapse treated in the rituximab era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Seshan, V.; Noy, A.; Horwitz, S. M.; Palomba, M. L.; Matasar, M. J.; Straus, D. J.; Hamlin, P. A.; Batlevi, C. L.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Impact of PET staging of follicular lymphoma on treatment outcomes and prognosis
    Meeting Abstract

    Alperovich, A.; Batlevi, C. L.; Intlekofer, A. M.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, A. J.; Gerecitano, J.; Hamlin, P. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save